An RCT study of the effect of oral immune enteral nutrition preparations on clinical outcomes in patients discharged from hospital after surgery for malnourished colorectal tumors

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400087249

Enrollment

Unknown

Registered

2024-07-23

Start date

2023-06-01

Completion date

Unknown

Last updated

2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

oral immune enteral nutrition preparation :This was administered alongside standard post-discharge interventions and the dosage of oral immune enteral nutrition was determined based on the patients b

oral nutritional enteral preparation:The oral nutrition group received oral nutritional preparation (consisting of 1.2 g/100 mL monounsaturated fatty acids, with an energy density of approximately 1.2

conventional diet. :The conventional group received only routine post-discharge management without nutritional intervention, including a regular diet, discomfort follow-up, and regular outpatient revi

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients who have been discharged from the hospital after undergoing laparoscopic/robotic radical resection of colorectal cancer. (2) Patients who meet the criteria for malnutrition based on the GLIM standard at the time of discharge. (3) Patients aged between 18 and 80 years. (4) Patients without significant cardiopulmonary, hepatic, or renal diseases. (5) Patients who have received oral nutrition during the perioperative period and have tolerated it well. (6) Patients who have provided informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients who do not meet the criteria for malnutrition based on the GLIM assessment at the time of discharge. (2) Pregnant women. (3) Patients who are unable to mobilize due to limb-related reasons at the time of discharge. (4) Patients who are on long-term use of hormones.

Design outcomes

Primary

Measure	Time frame
Skeletal muscle index;chemotherapy tolerance;	—

Secondary

Measure	Time frame
Gastrointestinal Functional Status Scale ;quality of life scores ;weight;total protein;albumin;haemoglobin ;BMI;	—

Countries

China

Contacts

Public ContactSundali

The Second Affiliated Hospital of Kunming Medical University

destinyky@163.com+86 135 7704 7806

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026